Huons Global postpones EGM and withdraws proxy solicitation due to unresolved cross-listing guidelines, delaying subsidiary merger vote

Huons Global's board decided on June 22, 2026 to postpone the extraordinary general meeting originally scheduled for July 3, 2026 and withdraw the proxy solicitation.
The postponement is due to unresolved cross-listing guidelines regarding the voting procedure for the merger between its subsidiaries Huons and Huons Lab, to avoid confusion and ensure fairness for shareholders.
The board will reschedule the meeting after the guidelines are announced; the merger aims to combine Huons Lab's bio pipeline with Huons's R&D infrastructure and capital to create synergies and enhance long-term enterprise value.
Huons Global holds 452,187 treasury shares and previously disclosed a board-approved in-kind dividend plan upon completion of the merger.
[AI Summary]The postponement delays short-term capital changes from the subsidiary merger but does not alter its strategic rationale or growth potential. The presence of treasury shares and planned in-kind dividend provides some shareholder return support, resulting in a neutral near-term stock impact.